Ditah Ivo, Al Bawardy Badr, Gonzalez Humberto C, Saberi Behnam, Ditah Callistus, Kamath Patrick S, Charlton Michael
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Department of Transplant Surgery, Methodist University Hospital, University of Tennessee, Memphis, Tennessee, USA.
Am J Gastroenterol. 2015 Aug;110(8):1126-33. doi: 10.1038/ajg.2015.31. Epub 2015 Mar 10.
Identifying barriers to access to hepatitis C virus (HCV) treatment among screen detected subjects is critical for any public health strategy aimed at controlling HCV infection in the general population.
Data from the National Health and Nutrition Examination Survey HCV Follow-up study from 2001 to 2010 were used. Participants who tested positive for HCV were sent a letter informing them of their test results and advised to pursue further evaluation. Information on HCV transmission and its potential complications was also provided to all positive participants. These subjects were recontacted 6 months after notification to determine what action they had taken regarding the positive result.
Of 38,025 participants, 502 tested positive for HCV infection, giving a prevalence of 1.3% (95% confidence interval (CI) 0.8%, 1.8%). A total of 205 subjects participated in the 6-month follow-up interview. Those who could not be reached were more likely to be less educated, injecting drugs, and not to have health insurance. Half (50.2%) of the positive individuals were not aware of their status before notification. A total of 166 (81%) had pursued further evaluation. Only 18 (26.9%) received therapy. The main reason for not receiving treatment was high cost (19.4%). In adjusted analysis, the only barrier to pursuing downstream HCV care was the lack of health insurance (2.76, 95% CI 1.54, 7.69; P=0.007).
This study suggests that the lack of health insurance may attenuate the theoretical benefits of a screening program that identifies asymptomatic HCV-infected individuals who are less likely to pursue downstream care.
识别筛查出的丙型肝炎病毒(HCV)感染者接受治疗的障碍,对于任何旨在控制普通人群中HCV感染的公共卫生策略而言都至关重要。
使用了2001年至2010年国家健康与营养检查调查HCV随访研究的数据。HCV检测呈阳性的参与者收到一封信,告知他们检测结果,并建议他们进行进一步评估。还向所有阳性参与者提供了有关HCV传播及其潜在并发症的信息。在通知6个月后再次联系这些受试者,以确定他们对阳性结果采取了什么行动。
在38025名参与者中,502人HCV感染检测呈阳性,患病率为1.3%(95%置信区间(CI)0.8%,1.8%)。共有205名受试者参与了6个月的随访访谈。无法联系到的人更有可能受教育程度较低、注射毒品且没有医疗保险。一半(50.2%)的阳性个体在收到通知之前不知道自己的状况。共有166人(81%)进行了进一步评估。只有18人(26.9%)接受了治疗。未接受治疗的主要原因是费用高昂(19.4%)。在调整分析中,寻求后续HCV治疗的唯一障碍是缺乏医疗保险(2.76,95%CI 1.54,7.69;P = 0.007)。
本研究表明,缺乏医疗保险可能会削弱筛查计划的理论益处,该筛查计划旨在识别不太可能寻求后续治疗的无症状HCV感染者。